SEC Form 4	
------------	--

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

			л стл			C 7 M									
FORM 4 ON TED 317					Washing		OMB APPROVAL								
Section 16. Fo	orm 4 or Form 5 ay continue. See	STA		ed pursua	F CHANGE	of the S	ecurit	ies Exchange A	ct of 193	_	IF	OMB Number: Estimated average bu hours per response:	3235-0287 rden 0.5		
FORM 4       UNITED 5         Check this box if no longer subject to obligations may continue. See Instruction 1(b).       STATE         1. Name and Address of Reporting Person*       WANG JUNFENG         (Last)       (First)       (Middle)         C/O BIONANO GENOMICS, INC.       9640 TOWNE CENTRE DRIVE, SUITE 100         (Street)       SAN DIEGO       CA         SAN DIEGO       CA       92121         (City)       (State)       (Zip)         Table I - Non-LI         1. Title of Security (Instr. 3)       2. Date         Common Stock       (Common Stock       (Common Stock)					er Name <b>and</b> Ticker Tano Genomic				(Cheo	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner					
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).   I. Name and Address of Reporting Person <sup>*</sup> WANG JUNFENG  (Last) (First) (Middle) C/O BIONANO GENOMICS, INC. 9640 TOWNE CENTRE DRIVE, SUITE 100 (Street) SAN DIEGO CA 92121 (City) (State) (Zip) Table I - Nor 1. Title of Security (Instr. 3)  Common Stock				3. Date of Earliest Transaction (Month/Day/Year) 08/23/2018							Officer (give title Other (specify below) below)				
					endment, Date of (	Driginal	Filed	(Month/Day/Yea		6. Individual or Joint/Group Filing (Check Applicable Line X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)														
		Table I - No				1	, Dis			-	1		1		
1. Title of Securi	ity (Instr. 3)		2. Transa Date (Month/D		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)		4. Securities A Disposed Of (E	cquired (/ )) (Instr. 3	A) or , 4 and 5)	5. Amount of Securities Beneficially Owned Followin	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Stock	k		08/23/	/2018		С		199,653	A	(1)	199,653	I	By entities affiliated with LC Fund VI, L.P. <sup>(2)</sup>		
Common Stock	k		08/23/	/2018		С		150,550	A	(1)	350,203	I	By entities affiliated with LC Fund VI, L.P. <sup>(3)</sup>		
Common Stock	k		08/23/	/2018		С		637,984	A	(1)	988,187	I	By entities affiliated with LC Fund VI, L.P. <sup>(4)</sup>		
Common Stock	k		08/23/	/2018		с		784,728	A	(5)	1,772,915	i I	By LC Healthcare Fund I, L.P. <sup>(6)</sup>		
													By Rosy		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

С

1,134,000

A

(7)

2,906,915

Shine

Limited<sup>(8)</sup>

I

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Deri Seci Acq Disp	umber of vative urities uired (A) or posed of (D) tr. 3, 4 and 5)	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title an of Securit Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Transaction(s (Instr. 4)			
Series C Convertible Preferred Stock	(1)	08/23/2018		С			8,545,184 <sup>(1)</sup>	(1)	(1)	Common Stock	199,653	\$0.00	0	I	By entities affiliated with LC Fund VI, L.P. <sup>(2)</sup>
Series D Convertible Preferred Stock	(1)	08/23/2018		С			6,443,565 <sup>(1)</sup>	(1)	(1)	Common Stock	150,550	\$0.00	0	I	By entities affiliated with LC Fund VI, L.P. <sup>(3)</sup>
Series D-1 Convertible Preferred Stock	(1)	08/23/2018		С			27,305,708 <sup>(1)</sup>	(1)	(1)	Common Stock	637,984	\$0.00	0	I	By entities affiliated with LC Fund VI, L.P. <sup>(4)</sup>

Explanation of Responses:

Common Stock

1. Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date.

08/23/2018

2. The shares are held as follows: 191,667 shares held by LC Fund VI, L.P. ("LC Fund") and 7,986 shares held by LC Parallel Fund VI, L.P. ("Parallel Fund") LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company ("Legend Capital"). The Reporting Person is a Managing Director of Legend Capital and disclaims beneficial ownership with respect to these securities, except to the

## extent of his pecuniary interest therein.

3. The shares are held as follows: 143,533 shares held by LC Fund and 7,017 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is a Managing Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.

4. The shares are held as follows: 91,700 shares held by LC Fund, 540,631 shares held by Parallel Fund and 5,653 shares held by LC Healthcare Fund I, L.P. ("Healthcare Fund"). LC Fund, Parallel Fund and Healthcare Fund are controlled and managed by Legend Capital. The Reporting Person is a Managing Director of Legend Capital and disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.

5. Represents the conversion of an outstanding convertible promissory note in the principal amount of \$3,460,000, plus \$144,846.03 accrued interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of \$6.125 per share.

6. Healthcare Fund is controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is a Managing Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein.

7. Represents the conversion of an outstanding convertible promissory note in the principal amount of \$5,000,000, plus \$209,315.07 accrued interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of \$6.125 per share.

8. Rosy Shine Limited is ultimately controlled and managed by Legend Holdings, a limited liability Chinese joint stock company listed on a Stock Exchange of Hong Kong (3396), which is controlled by its board of directors. The board of directors of Legend Holdings has sole voting and investment power over the shares held by Rosy Shine Limited. None of the members of the board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares.

**Remarks:** 

/s/ Heather Adams, Attorney-in-08/27/2018

\*\* Signature of Reporting Person Date

fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.